Akero Therapeutics, Inc. — Director's Dealing 2020

Jul 11, 2020

SEC Form 4/A — Form 4/A

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2020-01-02

Reporting Person: Versant Venture Capital VI, L.P. (10% Owner)
Reporting Person: Versant Ventures VI GP, L.P. (10% Owner)
Reporting Person: Versant Ventures VI GP-GP, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-02	Common Stock	S	10952	$19.89	Disposed	3645633	Indirect
2020-01-02	Common Stock	S	3900	$21.2	Disposed	3641733	Indirect
2020-01-02	Common Stock	S	1000	$22.17	Disposed	3640733	Indirect
2020-01-02	Common Stock	J	684143	—	Disposed	2956590	Indirect
2020-01-02	Common Stock	J	13683	—	Acquired	13683	Indirect
2020-01-02	Common Stock	J	13683	—	Disposed	0	Indirect
2020-01-02	Common Stock	J	11803	—	Acquired	11803	Indirect
2020-01-02	Common Stock	J	11803	—	Disposed	0	Indirect
2020-01-03	Common Stock	S	3100	$19.18	Disposed	2953490	Indirect
2020-01-03	Common Stock	S	100	$20.27	Disposed	2953390	Indirect
2020-01-06	Common Stock	S	4968	$17.68	Disposed	2948422	Indirect
2020-01-06	Common Stock	S	6101	$18.32	Disposed	2942321	Indirect
2020-01-06	Common Stock	S	42323	$19.93	Disposed	2899998	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F2: These sales were executed in multiple trades at prices ranging from $19.56 to $20.26. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F3: These sales were executed in multiple trades at prices ranging from $20.87 to $21.56. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F4: These sales were executed in multiple trades at prices ranging from $22.00 to $22.25. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F5: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital VI, L.P. ("Versant VI") without consideration to its partners.

F6: Represents a change in the form of ownership of Versant Ventures VI GP, LP ("Versant GP LP") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Versant VI.

F7: The shares are held by Versant GP LP. Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and may be deemed to have voting and investment power over the securities held by Versant GP LP and as a result may be deemed to have beneficial ownership over such securities. Versant GP LLC disclaims beneficial ownership over these securities except to the extent of its pecuniary interest therein.

F8: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant GP LP without consideration to its partners.

F9: Represents a change in the form of ownership of Versant GP LLC by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Versant GP LP.

F10: The shares are held by Versant GP LLC.

F11: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant GP LLC without consideration to its members.

F12: These sales were executed in multiple trades at prices ranging from $19.00 to $19.48. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F13: These sales were executed in multiple trades at prices ranging from $20.25 to $20.32. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F14: These sales were executed in multiple trades at prices ranging from $17.00 to $17.98. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F15: These sales were executed in multiple trades at prices ranging from $18.00 to $18.99. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F16: These sales were executed in multiple trades at prices ranging from $19.55 to $20.22. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.

F17: These shares are owned directly by Versant VI. Versant GP LP is the general partner of Versant VI and Versant GP LLC is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein.